Weinberg OK, Siddon A, Madanat YF, Gagan J, Arber DA, Dal Cin P (2022) TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML.Blood Adv 6(9):2847–2853. PMID: 35073573; PMCID: PMC9092405. https://doi.org/10.1182/bloodadvances.2021006239

Zbyslaw Sondka NB, Dhir D, Carvalho-Silva S, Jupe, Madhumita K, McLaren et al (2024) COSMIC: a curated database of somatic variants and clinical data for cancer. Nucleic Acids Res 52(D1):D1210–D1217. https://doi.org/10.1093/nar/gkad986

Article  CAS  PubMed  Google Scholar 

Eisfeld AK, Kohlschmidt J, Mrózek K, Mims A, Walker CJ, Blachly JS (2018) NF1 mutations are recurrent in adult acute myeloid leukemia and confer poor outcome. Leukemia 32(12):2536–2545. https://doi.org/10.1038/s41375-018-0147-4Epub 2018 Jun 5. PMID: 29872168; PMCID: PMC6281863

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jasek M, Gondek LP, Bejanyan N, Tiu R, Huh J, Theil KS, O’Keefe C, McDevitt MA, Maciejewski JP (2010) TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p. Leukemia 24(1):216–219. https://doi.org/10.1038/leu.2009.189Epub 2009 Sep 17. PMID: 19759556; PMCID: PMC2806506

Article  CAS  PubMed  Google Scholar 

Zhang L, Abro B, Campbell A, Ding Y (2024) TP53 mutations in myeloid neoplasms: implications for accurate laboratory detection, diagnosis, and treatment. Lab Med 55(6):686–699. https://doi.org/10.1093/labmed/lmae048PMID: 39001691; PMCID: PMC11532620

Article  PubMed  PubMed Central  Google Scholar